Veterinary Drug terms — page 10 | HESTIA Glossary

Browse all 1,061 veterinary drug terms HESTIA uses to describe agricultural data — with definitions and synonyms. Free and open.

Flavin adenine dinucleotide Riboflavine 5'-(trihydrogen diphosphate)-5'-5'-ester with adenosine; Flavin-adenine dinucleotide; 4-26-00-03632 (Beilstein Handbook Reference)
Flavin mononucleotide Riboflavine 5'-(dihydrogen phosphate); Flavin mononucleotide; 4-26-00-02554 (Beilstein Handbook Reference)
Fleroxacin 6,8-Difluoro-1-(2-fluoroethyl)-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; Fleroxacin; AM 833
Florfenicol 2,2-Dichloro-N-[(1S,2R)-1-(fluoromethyl)-2-hydroxy-2-[4-(methylsulfonyl)phenyl]ethyl]acetamide; Florfenicol; 73231-34-2; Nuflor; (-)-Florfenicol; Sch-25298; 76639-94-6; Nuflor gold; Sch 25298; florphenicol; C12H14Cl2FNO4S; Florfenicol [USAN:INN:BAN]; UNII-9J97307Y1H; 2,2-dichloro-N-[(1R,2S)-3-fluoro-1-hydroxy-1-(4-methylsulfonylphenyl)propan-2-yl]acetamide; CHEBI:87185; D-threo-2,2-Dichloro-N-(alpha-(fluoromethyl)-beta-hydroxy-p-(methylsulfonyl)phenethyl)acetamide; 9J97307Y1H; 2,2-Dichloro-N-(1-(fluoromethyl)-2-hydroxy-2-(4-(methylsulfonyl)phenyl)ethyl)acetamide; 2,2-Dichloro-N-[(1R,2S)-3-fluoro-1-hydroxy-1-(4-methylsulfonylphenyl)-2-propyl]acetamide; DSSTox_CID_25500; DSSTox_RID_80918; DSSTox_GSID_45500; Aquafen; 2,2-Dichloro-N-((alphaS,betaR)-alpha-(fluoromethyl)-beta-hydroxy-p-(methylsulfonyl)phenethyl)acetamide; Acetamide, 2,2-dichloro-N-((1S,2R)-1-(fluoromethyl)-2-hydroxy-2-(4-(methylsulfonyl)phenyl)ethyl)-; Acetamide, 2,2-dichloro-N-(1-(fluoromethyl)-2-hydroxy-2-(4-(methylsulfonyl)phenyl)ethyl)-, (R-(R*,S*))-; Benzenesulfonic acid, 4-(2-((dichloroacetyl)amino)-3-fluoro-1-hydroxypropyl)-, methyl ester, (R-(R*,S*))-; NCGC00016922-01; CAS-73231-34-2; Nuflor (TN); 3-fluorothiamphenicol; PubChem13648; thiamphenicol, 3-fluoro; Prestwick0_000955; Prestwick1_000955; Prestwick2_000955; Prestwick3_000955; Florfenicol (USAN/INN); SCHEMBL49425; BSPBio_000950; MLS002154071; SPBio_003099; BPBio1_001046; CHEMBL1241590; DTXSID9045500; (-)-Florfenicol; SCH-25298; AYIRNRDRBQJXIF-NXEZZACHSA-N; D-(-)-threo-2-Dichloroacetamido-3-fluoro-1-(4-methylsulfonylphenyl)-1-propanol; HMS1570P12; HMS2090I10; HMS2097P12; HMS2230K18; HMS3714P12; ZINC537733; ACT06682; HY-B1374; KS-00000G9G; Aquafen|||Nuflor|||SCH-25298; Tox21_110683; MFCD00864834; s4201; AKOS015889457; Tox21_110683_1; AC-4340; API0002713; CCG-220955; CS-4857; DB11413; KS-5028; NCGC00179366-01; NCGC00179366-03; NCGC00179366-04; [R-(R*,S*)]-2,2-Dichloro-N-[1-(fluoromethyl)-2-hydroxy-2-[4-(methylsulfonyl)phenyl]ethyl]acetamide; 2,2-Dichloro-N-[(1S,2R)-1-(fluoromethyl)-2-hydroxy-2-[4-(methylsulfonyl)phenyl]ethyl]acetamide; LS-31853; SC-16844; SC-59762; SMR001233384; AB0008500; AB1009284; (methylsulfonyl)phenyl)propan-2-yl)acetamide; AB00513976; F0811; FT-0630821; FT-0630848; SW197224-3; D04194; J10454; AB00513976_09; 231F342; A838774; Q408400; Florfenicol, analytical standard, for drug analysis; BRD-K11298197-001-03-9; 2,2-dichloro-N-((1R,2S)-3-fluoro-1-hydroxy-1-(4-; (1R,2S)-2-DICHLOROACETAMIDO-3-FLUORO-1-[4-(METHYLSULFONYL) PHENYL]-1-PROPANOL; (1R,2S)-2-dichloroacetamido-3-fluoro-1-[4-(methylsulfonyl)phenyl]-1-propanol; 2,2-bis(chloranyl)-N-[(1R,2S)-3-fluoranyl-1-(4-methylsulfonylphenyl)-1-oxidanyl-propan-2-yl]ethanamide; 2,2-Dichloro-N-((1R,2S)-3-fluoro-1-hydroxy-1-(4-(methylsulfonyl)phenyl)propan-2-yl)acetamide; 2,2-dichloro-N-[(1R,2R)-3-fluoro-1-hydroxy-1-(4-methylsulfonylphenyl)propan-2-yl]acetamide; 2,2-dichloro-N-[(1R,2S)-3-fluoro-1-hydroxy-1-(4-methanesulfonylphenyl)propan-2-yl]acetamide; 2,2-dichloro-N-{(1R,2S)-3-fluoro-1-hydroxy-1-[4-(methanesulfonyl)phenyl]propan-2-yl}acetamide; 81588-76-3; Aquafen; Nuflor; SCH-25298; [R-(R*,S*)]-2,2-Dichloro-N-[1-(fluoromethyl)-2-hydroxy-2-[4-(methylsulfonyl)phenyl]ethyl]acetamide; Benzenesulfonic acid, 4-(2-((dichloroacetyl)amino)-3-fluoro-1-hydroxypropyl)-,methyl ester, (R-(R*,S*))-; Florfenicol [USAN:INN:BAN]; 2,2-Dichloro-N-(1-(fluoromethyl)-2-hydroxy-2-(4-(methylsulfonyl)phenyl)ethyl)acetamide
Floxuridine 2'-Deoxy-5-fluorouridine; Foxuridine; 50-91-9; 5-Fluorodeoxyuridine; 2'-Deoxy-5-fluorouridine; Fluorodeoxyuridine; FUDR; Floxuridin; Deoxyfluorouridine; Fluoruridine deoxyribose; 5-Fluoro-2'-deoxyuridine; 5FdU; Floxuridinum; Floxiridina; 5-Fluoro-2-desoxyuridine; FdUrd; 5 Fluorodeoxyuridine; beta-5-Fluoro-2'-deoxyuridine; Floxuridinum [INN-Latin]; 5-Fluorouracil 2'-deoxyriboside; Floxiridina [INN-Spanish]; 5-fluoro-1-((2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidine-2,4(1h,3h)-dione; 5-Fluoro-2-deoxyuridine; 5-Fluorouracil deoxyriboside; 5-FdUrd; 1-(2-Deoxy-beta-D-ribofuranosyl)-5-fluorouracil; 1beta-D-2'-Deoxyribofuranosyl-5-flurouracil; 1-beta-D-2'-Deoxyribofuranosyl-5-flurouracil; Uridine, 2'-deoxy-5-fluoro-; NSC-27640; FDUR; UNII-039LU44I5M; 5-fluoro-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,3,4-tetrahydropyrimidine-2,4-dione; (+)-5-fluoro-2'-deoxyuridine; CHEBI:60761; HSDB 3227; 5-FUDR; EINECS 200-072-5; (+)-5-fluorodeoxyuridine; CHEMBL917; BRN 0090221; AI3-50691; MLS000069439; 039LU44I5M; NSC 27640; Uridine, 2'-deoxy-5'-fluoro-; NCGC00023722-05; SMR000059051; DSSTox_CID_3057; 5-Fluor-1-(beta-2'-deoxyribofuranosyl)pyrimidin-2,4(1H,3H)-dion [Czech]; Ro 5-0360; DSSTox_RID_76855; DSSTox_GSID_23057; FdU; Uridine, 2'-deoxy-5-fluoro; (+)-5-Fluoro-2 -deoxyuridine; CAS-50-91-9; (+)-5-Fluoro-2'-deoxyuridine, 99+%; 1-[(4S,2R,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-fluoro-1,3-dihydropyri midine-2,4-dione; 5-Fluoro-1-((2R,4S,5R)-4-hydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-1H-pyrimidine-2,4-dione; Floxuridine [USAN:INN]; FUDR (TN); 5-Fluoro-2'-deoxy-beta-uridine; floxidine; Fluoxuridine; NSC27640; Floxuridine [USAN:USP:INN]; 5-floxuridine; Floxuridine,(S); 5-Fluoro-dUrd; MFCD00006530; Floxuridine (Fludara); PubChem21054; Floxuridine (USP/INN); Opera_ID_1559; 2-deoxy-5'-fluorouridine; 2; -Deoxy-5-fluorouridine; Epitope ID:138108; SCHEMBL4424; 2''-deoxy-5-fluorouridine; 2'-deoxy-5-fluoro uridine; 5-fluoro-2''-deoxyuridine; 5-24-06-00291 (Beilstein Handbook Reference); KSC593G8F; MLS002695934; MLS006011768; 5-fluoro-2''-Deoxy-uridine; 2'-deoxy-5-fluoro-d-uridine; GTPL4801; DTXSID3023057; CTK4J3382; ODKNJVUHOIMIIZ-RRKCRQDMSA-N; HMS2090I12; HMS2230N22; HMS3715A11; BCP02871; HY-B0097; KS-000002EU; ZINC3813010; Tox21_110892; 5-Fluor-1-(beta-2'-deoxyribofuranosyl)pyrimidin-2,4(1H,3H)-dion; ANW-31161; BBL033765; BDBM50340678; CF-072; s1299; STK801909; AKOS005622662; Tox21_110892_1; BCP9000691; CCG-220965; CS-1827; DB00322; MCULE-4890053166; PS-7520; SRI-9246-15; SRI-9246_18; uridine, 2-18O-2'-deoxy-5-fluoro-; uridine, 3-15N-2'-deoxy-5-fluoro-; NCGC00023722-03; NCGC00023722-06; NCGC00023722-08; uridine, 5'-18O-2'-deoxy-5-fluoro-; AC-16391; BR-24802; CPD000059051; SAM002548946; SC-18561; ST056942; BCP0726000269; AB0069044; LS-160820; D2235; uridine, 2,5'-18O2-2'-deoxy-5-fluoro-; EN300-52649; C11736; D04197; J10098; S-2808; 15184-EP2272827A1; 15184-EP2275420A1; 15184-EP2295055A2; 15184-EP2295416A2; 15184-EP2295426A1; 15184-EP2295427A1; 15184-EP2298748A2; 15184-EP2298764A1; 15184-EP2298765A1; 15184-EP2298768A1; 15184-EP2305642A2; 15184-EP2311453A1; 15184-EP2311808A1; 15184-EP2311829A1; 15184-EP2311840A1; 15184-EP2311842A2; 15184-EP2316832A1; 15184-EP2316833A1; 006F530; 124816-EP2295426A1; 124816-EP2295427A1; SR-01; J-700034; Q5462356; SR-01-2; BRD-K47832606-001-26-9; BRD-K47832606-001-30-1; 5-Fluoro-2'-deoxyuridine, thymidylate synthase inhibitor; Z802671482; 1-(beta-D-2-deoxy-erythro-pentofuranosyl)-5-fluorouracil; Floxuridine, United States Pharmacopeia (USP) Reference Standard; 5-Fluoro-1-(4-hydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-1H-pyrimidine-2,4-dione; 136353-77-0; 136353-81-6; 136353-85-0; 2'-Deoxy-5-fluorouridine Floxuridine C9H11FN2O5 246.20 148-151 degrees 50-91-9 "14,4112" 200-072-5 MFCD00006530 YU7535000 UN2811 6.1 N; 396726-50-4; 5-fluoro-1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione; 5-fluoro-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidine-2,4-dione; 5-FUdR|||5-Fluorodeoxyuridine|||5-Fluoro-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione; Floxuridine; 5-24-06-00291 (Beilstein Handbook Reference)
Fluconazole alpha-(2,4-Difluorophenyl)-alpha-(1H-1,2,4-triazol-1-ylmethyl)-1H-1,2,4-triazole-1-ethanol; fluconazole; 86386-73-4; Diflucan; Triflucan; Biozolene; Elazor; Biocanol; Fluconazol; Fungata; Fluconazolum; Flucazol; Flucostat; Flukezol; Flunizol; Pritenzol; Zonal; UK 49858; Alflucoz; Oxifugol; 2-(2,4-DIFLUOROPHENYL)-1,3-DI(1H-1,2,4-TRIAZOL-1-YL)PROPAN-2-OL; Canzol; Cryptal; Dimycon; Flusol; Forcan; Syscan; Zoltec; Baten; Mutum; Zemyc; 2-(2,4-Difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol; Fluconazol [Spanish]; Fluconazolum [Latin]; UK-49858; DRG-0005; UNII-8VZV102JFY; 2-(2,4-difluorophenyl)-1,3-bis(1,2,4-triazol-1-yl)propan-2-ol; CCRIS 7211; C13H12F2N6O; DIFLUCAN IN SODIUM CHLORIDE 0.9%; HSDB 7420; CHEMBL106; 2-(2,4-Difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)-2-propanol; DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER; 8VZV102JFY; 2,4-Difluoro-alpha,alpha-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol; CHEBI:46081; RFHAOTPXVQNOHP-UHFFFAOYSA-N; 2-(2,4-Difluorophenyl)-1,3-di-1H-1,2,4-triazol-1-ylpropan-2-ol; Fluconazole, 98%; 1H-1,2,4-Triazole-1-ethanol, alpha-(2,4-difluorophenyl)-alpha-(1H-1,2,4-triazol-1-ylmethyl)-; alpha-(2,4-Difluorophenyl)-alpha-(1H-1,2,4-triazol-1-ylmethyl)-1H-1,2,4-triazole-1-ethanol; difluconazole; NCGC00095089-01; Flunazol; Fluzone; Loitin; DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER; DSSTox_CID_627; DSSTox_RID_75701; DSSTox_GSID_20627; 123631-92-5; FLC; Diflazon; Fuconal; Triconal; Diflucan (TN); CPD000471882; SMR000471882; CAS-86386-73-4; FLCZ; Fluconazole & hGCSF; SR-01000765440; Fluconazole [USAN:INN:BAN:JAN]; Fluconazole in sodium chloride 0.9%; Flucoral; 2-(2,4-difluorophenyl)-1,3-di(1,2,4-triazolyl)propan-2-ol; Fluconazole & MC-510,011; Fluconazole (f); Fluconazole,(S); Fluconazole in dextrose 5% in plastic container; 2,4-Difluoro-alpha,alpha-1-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol; Fluzon [Antifungal]; Fluconazole [USAN]; KS-1059; Fluconazole [USAN:USP:INN:BAN:JAN]; Fluconazole in sodium chloride 0.9% in plastic container; Fluconazole in combination with MGCD290; Spectrum_001654; Spectrum2_001607; Spectrum3_001912; Spectrum4_000090; Spectrum5_001277; F0677; MGCD290 and Fluconazole; cid_3365; MG-3290 and Fluconazole; SCHEMBL3151; BSPBio_003504; KBioGR_000360; KBioSS_002134; MLS001066394; MLS001165780; MLS001195645; MLS001304713; MLS001306492; MLS006011884; BIDD:GT0799; DivK1c_001030; SPECTRUM1503975; SPBio_001613; 1-p-tolylpyridin-2(1H)-one; ZINC4009; DTXSID3020627; BDBM25817; CTK4B3573; Fluconazole (JP17/USAN/INN); HMS503M21; KBio1_001030; KBio2_002134; KBio2_004702; KBio2_007270; KBio3_003009; NINDS_001030; HMS1922O10; HMS2090I20; HMS2093M21; HMS2230O22; HMS3259H13; HMS3373I19; HMS3654P15; HMS3715F21; HMS3748G19; Pharmakon1600-01503975; BCP28522; Fluconazole 2.0 mg/ml in Methanol; HY-B0101; KS-000000NR; 1,2,4-triazol-1-yl)propan-2-ol; Tox21_111419; Tox21_202240; Tox21_300581; 2-(2,4-Difluoro-phenyl)-1,3-bis-[1,2,4]triazol-1-yl-propan-2-ol; ABP001077; AC-428; ANW-42860; BBL005614; CCG-39065; CF0055; DL-407; Fluconazole & Human recombinant granulocyte colony stimulating factor; KM2402; MFCD00274549; NSC758661; s1331; SBB066063; STK619301; AKOS000280854; Tox21_111419_1; CS-1835; DB00196; Fluconazole, >=98% (HPLC), powder; LS-1858; MCULE-8641424658; NC00650; NSC-758661; IDI1_001030; NCGC00095089-02; NCGC00095089-04; NCGC00095089-05; NCGC00095089-06; NCGC00095089-07; NCGC00095089-08; NCGC00095089-09; NCGC00095089-10; NCGC00095089-11; NCGC00254412-01; NCGC00259789-01; 2-(2,4-difluorophenyl)-1,3-di(1H-; SAM002589905; SAM002589957; SC-12182; SC-26357; SC-35622; SBI-0051880.P002; AB0008515; AB1010904; TR-038046; UK-049858; UK-49,858; FT-0626437; ST51039043; SW199616-2; EN300-53634; C07002; D00322; J10407; AB00052399-07; AB00052399-08; AB00052399_09; AB00052399_10; 386F734; A841625; Q411478; Q-201120; SR-01000765440-2; SR-01000765440-4; SR-01000765440-8; UK-49858; UK 49858; UK49858; BRD-K05977355-001-02-6; BRD-K05977355-001-09-1; F2173-0496; Z235354561; Fluconazole, European Pharmacopoeia (EP) Reference Standard; 2-(2,4-difluorophenyl)-1,3-bis(1,2,4-triazol-1-yl)-2-propanol; Fluconazole, United States Pharmacopeia (USP) Reference Standard; 2-[2,4-bis(fluoranyl)phenyl]-1,3-bis(1,2,4-triazol-1-yl)propan-2-ol; 86386-73-4,155347-36-7(H2O),159532-41-9(methanesulfonate); Fluconazole, Pharmaceutical Secondary Standard; Certified Reference Material; Fluconazole for peak identification, European Pharmacopoeia (EP) Reference Standard; Fluconazole solution, 2.0 mg/mL in methanol, ampule of 1 mL, certified reference material; .alpha.-(2,4-Difluorophenyl)-.alpha.-(1H-1,2,4-triazol-1-ylmethyl)-1H-1,2,4-triazole-1-ethanol; 340962-81-4; FLUCONAZOLE; ALPHA-(2,4-DIFLUOROPHENYL)-ALPHA-(1H-1,2,4-TRIAZOLE-1-YLMETHYL)-1H-1,2,4-TRIAZOLE-1-ETHANOL; ELAZOR; TRIFLUCAN; BIOZOLENE; Fluconazole; CCRIS 7211
Flufenamic acid 2-[[3-(Trifluoromethyl)phenyl]amino]benzoic acid; Flufenamic acid; C.I. 440
Flumazenil 8-fluoro-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylic acid, Ethyl ester; Flumazenil; Anexate
Flumequine 9-Fluoro-6,7-dihydro-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylic acid; Flumequine; EINECS 255-962-6
Flumethasone pivalate (6alpha,11beta,16alpha)-21-(2,2-Dimethyl-1-oxopropoxy)-6,9-difluoro-11,17-dihydroxy-16-methylpregna-1,4-diene-3,20-dione; Flumethasone pivalate; 6alpha,9alpha-Difluoro-16alpha-methylprednisolone 21-pivalate
Flunitrazepam 5-(2-Fluorophenyl)-1,3-dihydro-1-methyl-7-nitro-2H-1,4-benzodiazepin-2-one; flunitrazepam; Narcozep; Rohypnol; 1622-62-4; Roipnol; Fluninoc; Primun; flunipam; Flunitrazepamum; Flunitrazepamum [INN-Latin]; Silece; [3H]flunitrazepam; Ro 5-4200; Flunitrazepan; RO54200; RO-5-4200; 5-(2-fluorophenyl)-1-methyl-7-nitro-3H-1,4-benzodiazepin-2-one; Flunitrazepam [USAN:INN:BAN:JAN]; 5-(o-Fluorophenyl)-1,3-dihydro-1-methyl-7-nitro-2H-1,4-benzodiazepin-2-one; CCRIS 5287; UNII-620X0222FQ; HSDB 6960; 1-Methyl-7-nitro-5-(2-fluorophenyl)-3H-1,4-benzodiazepin-2(1H)-one; 1,3-Dihydro-5-(o-fluorophenyl)-1-methyl-7-nitro-2H-1,4-benzodiazepin-2-one; 2H-1,4-Benzodiazepin-2-one, 5-(2-fluorophenyl)-1,3-dihydro-1-methyl-7-nitro-; EINECS 216-597-8; BRN 0702691; CHEMBL13280; DEA No. 2763; Fluridrazepam; PPTYJKAXVCCBDU-UHFFFAOYSA-N; Ro-54200; 2H-1,4-BENZODIAZEPIN-2-ONE, 1,3-DIHYDRO-5-(2-FLUOROPHENYL)-1-METHYL-7-NITRO-; 620X0222FQ; 5-(2-fluorophenyl)-1,3-dihydro-1-methyl-7-nitro-2h-1,4-benzodiazepin-2-one; 5-(2-Fluorophenyl)-1-methyl-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 5-(2-Fluorophenyl)-1-methyl-7-nitro-1H-benzo[e][1,4]diazepin-2(3H)-one; 5-(2-fluorophenyl)-1-methyl-7-nitro-2,3-dihydro-1H-1,4-benzodiazepin-2-one; W-107962; flunidazepam; Rohypnol (TN); Hipnosedon; Flunita; Fluscand; Hypnodorm; Valsera; Hypnor; Primum; [3H]Rohypnol; Narcozep|||Rohypnol; SCHEMBL44169; 5-24-04-00350 (Beilstein Handbook Reference); MLS003899224; DivK1c_000981; GTPL4193; GTPL4360; DTXSID7023065; BDBM25878; CHEBI:31622; CTK6I1441; HMS503E03; KBio1_000981; N05CD03; NINDS_000981; Flunitrazepam (JP17/USAN/INN); ZINC3812994; 5-(2-Fluorophenyl)-1-methyl-7-nitro-3H-1,4-benzodiazepin-2(1H)-one; ANW-71935; NSC708829; Flunitrazepam 0.1 mg/ml in Methanol; Flunitrazepam 1.0 mg/ml in Methanol; AKOS005066009; DB01544; NSC-708829; IDI1_000981; LS-34296; SMR000058981; DB-043520; TC-160680; FT-0603567; D01230; Q62947; 622F624; A810363; Flunitrazepam solution, drug standard, 1.0 mg/mL in methanol; Flunitrazepam, European Pharmacopoeia (EP) Reference Standard; Flunitrazepam-13C6, 100 mug/mL in methanol, certified reference material; (E)-5-(2-fluorophenyl)-1-methyl-7-nitro-1H-benzo[e][1,4]diazepin-2(3H)-one; 1,3-dihydro-5-(2-fluorophenyl)-1-methyl-7-nitro-2H-1,4-benzodiazepin-2-one; 5-(2-Fluorophenyl)-1-methyl-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one #; 5-(2-Fluorophenyl)-1-methyl-7-nitro-1,3-dihydrobenzo[e][1,4]diazepin-2-one; Flunitrazepam solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material; Flunitrazepam; 5-24-04-00350 (Beilstein Handbook Reference)
Fluorescin 2-(3,6-Dihydroxy-9H-xanthen-9-yl)benzoic acid; Fluorescin; EINECS 208-252-5
Fluoxetine N-Methyl-gamma-[4-(trifluoromethyl)phenoxy]benzenepropanamine; Fluoxetine; (+) or (-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine
Fluoxetine hydrochloride N-Methyl-gamma-[4-(trifluoromethyl)phenoxy]benzenepropanamine, Hydrochloride (1:1); Fluoxetine hydrochloride; CCRIS 6150
Flurothyl 1,1'-Oxybis[2,2,2-trifluoroethane]; Flurothyl; 4-01-00-01371 (Beilstein Handbook Reference)
Flutamide 2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide; flutamide; 13311-84-7; Niftolide; Eulexin; Niftholide; 2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide; NFBA; niftolid; Drogenil; Flutamin; Cebatrol, veterinary; Sch 13521; Flutamida; Flutamidum; Sch-13521; 4'-Nitro-3'-trifluoromethylisobutyranilide; Ham's F-12 medium; Flutamidum [INN-Latin]; Flutamida [INN-Spanish]; 2-Methyl-N-(4-nitro-3-[trifluoromethyl]phenyl)propanamide; NSC 215876; Flutamide (Eulexin); CCRIS 7246; Propanamide, 2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-; alpha,alpha,alpha-Trifluoro-2-methyl-4'-nitro-m-propionotoluidide; UNII-76W6J0943E; C11H11F3N2O3; EINECS 236-341-9; CHEMBL806; BRN 2157663; 4-Nitro-3-(trifluoromethyl)isobutyranilide; CHEBI:5132; N-(4-NITRO-3-(TRIFLUOROMETHYL)PHENYL)ISOBUTYRAMIDE; Propanamide, 2-methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-; MKXKFYHWDHIYRV-UHFFFAOYSA-N; 76W6J0943E; NSC-215876; NCGC00015452-09; CPD000058187; Eulexine; Chimax; 4'-Nitro-3'-trifluoromethylisobutyramilide; CAS-13311-84-7; DSSTox_CID_11121; DSSTox_RID_78899; DSSTox_GSID_32004; Flutamide USP25; Prostandril; Odyne; m-Propionotoluidide, 2-methyl-4'-nitro-alpha,alpha,alpha-triflouro-; Flutamide(Eulexin); 37209-54-4; SMR000058187; Eulexin (TN); Flutamide [USAN:BAN:INN]; m-Propionotoluidide,.alpha.,.alpha.-trifluoro-; SR-01000075888; SCH13521; N1-[4-nitro-3-(trifluoromethyl)phenyl]-2-methylpropanamide; .alpha.,.alpha.-Trifluoro-2-methyl-4'-nitro-m-propionotoluidide; m-Propionotoluidide,.alpha.,.alpha.-trifluoro-2-methyl-4'-nitro-; 4'-Nitro-3'-(trifluoromethyl)isobutyranilide; Flutamide [USAN:USP:INN:BAN]; Flutamide,(S); Prestwick_228; MFCD00072009; NK-601; ACMC-20hidt; PubChem13536; Spectrum_001210; 2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propionamide; Prestwick0_000180; Prestwick1_000180; Prestwick2_000180; Prestwick3_000180; Spectrum2_001201; Spectrum3_001421; Spectrum4_000829; Spectrum5_001450; Lopac-F-9397; F0663; Flutamide (pubertal study); F 9397; SCHEMBL3934; Lopac0_000557; BSPBio_000079; BSPBio_003122; KBioGR_001377; KBioSS_001690; MLS000069634; MLS001065596; MLS002548892; DivK1c_000459; SPECTRUM1500995; SPBio_000982; SPBio_002000; Flutamide (JP17/USP/INN); BPBio1_000087; GTPL6943; DTXSID7032004; SCHEMBL12932289; CTK4B8363; HMS501G21; KBio1_000459; KBio2_001690; KBio2_004258; KBio2_006826; KBio3_002342; NINDS_000459; HMS1568D21; HMS1921O16; HMS2090I18; HMS2092O14; HMS2095D21; HMS2230P19; HMS3259I03; HMS3261P15; HMS3373C12; HMS3655G22; HMS3712D21; Pharmakon1600-01500995; BCP23006; HY-B0022; m-propionotoluidide,alpha,alpha,alpha-trifluoro-2-methyl-4'-nitro; ZINC3812944; Tox21_110154; Tox21_202169; Tox21_300536; Tox21_500557; BDBM50131270; CCG-39105; NSC147834; NSC215876; NSC757817; s1908; SBB006930; AKOS001025465; AKOS025243203; m-Propionotoluidide, .alpha.,.alpha.,.alpha.-trifluoro-2-methyl-4'-nitro-; Tox21_110154_1; AB02835; CS-2359; DB00499; KS-5091; LP00557; LS-2105; MCULE-7498839065; NC00451; NSC-147834; NSC-757817; SDCCGSBI-0050540.P004; IDI1_000459; KS-00000L22; NCGC00015452-01; NCGC00015452-02; NCGC00015452-03; NCGC00015452-04; NCGC00015452-05; NCGC00015452-06; NCGC00015452-07; NCGC00015452-08; NCGC00015452-10; NCGC00015452-11; NCGC00015452-12; NCGC00015452-13; NCGC00015452-14; NCGC00015452-15; NCGC00015452-16; NCGC00015452-19; NCGC00015452-20; NCGC00091460-01; NCGC00091460-02; NCGC00091460-03; NCGC00091460-04; NCGC00091460-05; NCGC00091460-06; NCGC00091460-07; NCGC00091460-08; NCGC00091460-09; NCGC00254495-01; NCGC00259718-01; NCGC00261242-01; AC-24192; AK499646; SAM002264612; SC-12180; ST058409; SBI-0050540.P003; AB0005010; AB1010911; DB-042163; 3'-Trifluoromethyl-4'-Nitro-Isobutyranilide; AB00052188; EU-0100557; FT-0626493; SW196536-4; 4''-nitro-3''-trifluoromethylisobutyranilide; C07653; D00586; J10037; K-4175; AB00052188-09; AB00052188_10; AB00052188_11; 311F847; A806562; Q418669; Q-201131; SR-01000075888-1; SR-01000075888-6; SR-01000075888-7; SR-01000075888-9; BRD-K28307902-001-05-0; Flutamide, certified reference material, TraceCERT(R); Z56755651; a,a,a-Trifluoro-2-methyl-4'-nitro- m-propionotoluidide; Flutamide, European Pharmacopoeia (EP) Reference Standard; 2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide #; Flutamide, United States Pharmacopeia (USP) Reference Standard; Propanamide,2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-; alpha,alpha,alpha-trifluoro-2-methyl-4''-nitro-m-propionotoluidide; m-Propionotoluidide, alpha,alpha,alpha-trifluoro-2-methyl-4'-nitro-; .alpha.,.alpha.,.alpha.-Trifluoro-2-methyl-4'-nitro-m-propionotoluidide; m-Propionotoluidide, 2-methyl-4'-nitro-.alpha.,.alpha.,.alpha.-trifluoro-; m-Propionotoluidide, alpha,alpha,alpha-trifluoro-2-methyl-4'-nitro- (8CI); Flutamide for system suitability, European Pharmacopoeia (EP) Reference Standard; PUBERTAL FLUTAMIDE STUDY (PUBERTAL STUDIES OF VINCLOZOLIN; METHOXYCHLOR; ETHINYL ESTRADIOL); Flutamide; BRN 2157663
Fluvastatin fluvastatin; 93957-54-1; Lescol; Cranoc; (+)-(3R,5S)-fluvastatin; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S)-fluvastatin; Fluvastatin [INN:BAN]; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; Canef; XU 62320; XU-62320; EN300-51915; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; C24H26FNO4; (3R,5S,E)-7-(3-(4-Fluorophenyl)-1-isopropyl-1H-indol-2-yl)-3,5-dihydroxyhept-6-enoic acid; Fluvastatin & Primycin; (E,3R,5S)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (-)-fluvastatin; (E,3R,5S)-7-[3-(4-fluorophenyl)-1-isopropyl-indol-2-yl]-3,5-dihydroxy-hept-6-enoic acid; PubChem10727; DSSTox_CID_636; Prestwick2_000859; SCHEMBL2846; 7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)-3,5-dihydroxy-6-heptenoate; DSSTox_RID_75707; DSSTox_GSID_20636; (3R,5S,6E)-rel-7-[3-(4-Fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptenoic acid; SCHEMBL556754; GTPL2951; DTXSID2020636; BDBM86704; CHEBI:38565; CHEBI:93160; FJLGEFLZQAZZCD-MCBHFWOFSA-N; HMS2089P06; HMS3259J15; Pharmakon1600-01504911; 6-Heptenoic acid, 7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)- 3,5-dihydroxy-, (3R,5S,6E)-rel-; 6-Heptenoic acid, 7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)- 3,5-dihydroxy-, (R*,S*-(E))-(+-)-; ACT03305; ZINC1886617; Tox21_302765; DL-108; NSC758896; API0002749; CCG-213323; CS-1226; LS-7404; NC00659; NSC-758896; (3R,5S)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; NCGC00256490-01; CPD001453708; HY-14664; SAM002548940; CAS-93957-54-1; CAS_93957-54-1; W-5176; 957F541; Q417942; SR-05000001489-1; BRD-K66296774-001-02-0; UNII-4L066368AS component FJLGEFLZQAZZCD-MCBHFWOFSA-N; (E)-(3R,5S)-7-[3-(4-Fluoro-phenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxy-hept-6-enoic acid; 6-Heptenoic acid, 7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)-3,5-dihydroxy-, (R*,S*-(E))-(+-)-; 6-Heptenoic acid, 7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-, (3R,5S,6E)-; Fluvastatin sodium L1483; fluvastatin; Fluvastatine; FluvastatiFluvastatinum; Fluvastatine [INN-French]; Fluvastatinum [INN-Latin]; Fluvastatina [INN-Spanish]; Cranoc; 93957-54-1; Fluindostatin; CHEBI:5136; CHEMBL350239; Fluvastatin [INN:BAN]; C24H26FNO4; XU 62-320; 155229-76-8; (3S,5R,E)-7-(3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl)-3,5-dihydroxyhept-6-enoic acid; XU 62320; XU-62320; (3S,5R,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3S,5R) Fluvastatin Sodium Salt; (+-)-fluvastatin; Fluvastatin (INN); Fluvas (TN); (3S,5R)-FLUVASTATIN SODIUM SALT; (3S,5R)-fluvastatin; Prestwick3_000859; rac-(3R,5S)-fluvastatin; SCHEMBL2847; SCHEMBL2849; BSPBio_000877; BIDD:GT0839; (-)-(3S,5R)-fluvastatin; (3S,5R)-(-)-fluvastatin; BPBio1_000965; CHEBI:38561; CHEBI:94603; HSDB 8366; 6-Heptenoic acid, 7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)- 3,5-dihydroxy-, (3R,5S,6E)-rel-; 6-Heptenoic acid, 7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)- 3,5-dihydroxy-, (R*,S*-(E))-(+-)-; ZINC1530639; BDBM50248235; AKOS015896650; DB01095; VA10958; SC-13324; RT-012676; C07014; D07983; BRD-K03602135-236-02-1; BRD-K39716612-236-01-1; UNII-4L066368AS component FJLGEFLZQAZZCD-JUFISIKESA-N; (3S,5R,6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (6E)-erythro7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; erythro-(E)-3,5-dihydroxy-7-[3'-(4''-fluorophenyl)-1'-(1''-methylethyl)indol-2'-yl]hept-6-enoic acid; rac-(3R,5S,6E)-7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)-3,5-dihydroxy-6-heptenoic acid; rac-(3R,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; fluvastatin; CHEBI:38562; FJLGEFLZQAZZCD-VAWYXSNFSA-N; (6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; 93957-54-1; SCHEMBL2848; SCHEMBL464787; CHEMBL2220442; CHEBI:95159; 1025085-49-7; BCP08213; EN300-295528; 28051-EP2269989A1; 28051-EP2270011A1; 28051-EP2272825A2; 28051-EP2272841A1; 28051-EP2280006A1; 28051-EP2280282A1; 28051-EP2281813A1; 28051-EP2284158A1; 28051-EP2287165A2; 28051-EP2287166A2; 28051-EP2292620A2; 28051-EP2295406A1; 28051-EP2295409A1; 28051-EP2298742A1; 28051-EP2298745A1; 28051-EP2298772A1; 28051-EP2298776A1; 28051-EP2298779A1; 28051-EP2301923A1; 28051-EP2301931A1; 28051-EP2301936A1; 28051-EP2308839A1; 28051-EP2314588A1; Q27117899; (6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; 7-[3-(4-Fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptenoic acid, sodium salt; fluvastatin; 93957-54-1; 7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1h-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; 7-[3-(4-fluorophenyl)-1-propan-2-yl-2-indolyl]-3,5-dihydroxy-6-heptenoic acid; CHEMBL2140067; CTK7J1864; (E,3R,5S)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; FJLGEFLZQAZZCD-UHFFFAOYSA-N; 1025085-49-7; Lapatinib Ditosylate (GW572016, GW2016); Q27166956; 7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-hept-6-enoic acid; (+/-)-7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptenoic acid; fluvastatin; (3S,5S)-fluvastatin; (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; CHEMBL170132; CHEBI:38568; (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; 93957-54-1; SCHEMBL678274; ZINC3830863; BDBM50139803; Q27117904; UNII-OT7W70P7E1 component FJLGEFLZQAZZCD-VVZAMHAXSA-N
Fluvoxamine (1E)-5-Methoxy-1-[4-(trifluoromethyl)phenyl]-1-pentanone O-(2-aminoethyl)oxime; Fluvoxamine; Fluvoxamina [INN-Spanish]
Folic acid N-[4-[[(2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid; N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid; Acfol (Spain)
Fomepizole 4-Methyl-1H-pyrazole; 4-Methylpyrazole; fomepizole; 4-Methyl-1H-pyrazole; 7554-65-6; Antizol; 4-Methylpyrazol; 1H-Pyrazole, 4-methyl-; Fomepizol; Fomepizolum; Fomepizol [INN-Spanish]; Fomepizolum [INN-Latin]; Antizol-vet; Fomepizole [USAN:INN]; 4-methyl pyrazole; PYRAZOLE, 4-METHYL-; UNII-83LCM6L2BY; CHEBI:5141; EINECS 231-445-0; MFCD00005245; BRN 0105204; 83LCM6L2BY; C4H6N2; RIKMMFOAQPJVMX-UHFFFAOYSA-N; 4-Methylpyrazole, 97%; Antizol (TN); Fomepizole [USAN:INN:BAN]; 4-methyl-pyrazole; Fomepizole, 99%; zlchem 884; Fomepizole (Antizol); 4-methyl-1h_pyrazole; PubChem13055; ACMC-209oys; Lopac-M-1387; M0774; EC 231-445-0; CHEMBL1308; Lopac0_000723; 5-23-05-00031 (Beilstein Handbook Reference); KSC377C7J; MLS001335923; Fomepizole (JAN/USAN/INN); DTXSID3040649; CTK2H7174; ZLD0345; s137; HMS3713H14; Pharmakon1600-01506159; ZINC897288; ACT05848; ACT08853; ALBB-016317; HY-B0876; KS-000001GS; ANW-36626; BBL015773; BDBM50226186; CL3422; NSC760365; s1717; SBB004402; STK256626; AKOS000265586; AB00390; AC-4833; ACN-004649; CCG-204808; DB01213; LS20097; MCULE-2732751720; NSC-760365; RTR-037683; SDCCGSBI-0050701.P003; TRA0026533; VP20110; NCGC00015646-01; NCGC00015646-02; NCGC00015646-03; NCGC00015646-04; NCGC00162231-01; 615557-09-0; AK-46480; BR-46480; SC-04749; SMR000059088; SY006499; SBI-0050701.P002; AB0018506; AB2000244; DB-022514; DB-094915; LS-128524; ST2411524; TR-037683; 4-methylpyrazole; Antizol; Antizol-Vet; Antizol; A9615; AM20100737; BB 0257933; FT-0626518; ST45123338; EN300-50246; C-5324; C07837; D00707; AB00918526_06; AB00918526_07; 554M656; Q416410; Q-101886; Z969563038; 4PZ; Fomepizole; 5-23-05-00031 (Beilstein Handbook Reference)
Formestane 4-Hydroxyandrost-4-ene-3,17-dione; formestane; 566-48-3; 4-Hydroxyandrost-4-ene-3,17-dione; 4-Hydroxyandrostenedione; Lentaron; CGP-32349; Lentaron(R); NSC 282175; 4-OH-A; B, Aromatase inhibitor; 4-Hydroxy-4-androstene-3,17-dione; 17-dione; 4-OHA; CGP 32349; Formestane [INN:BAN]; ANDROST-4-ENE-3,17-DIONE, 4-HYDROXY-; UNII-PUB9T8T355; CCRIS 7483; 4-OHAD; 4-Hydroxy-delta(sub 4)-androstenedione; BRN 1889793; MLS000028826; MLS002153359; PUB9T8T355; CHEBI:75172; 4-hydroxy-Delta(4)-androstenedione; (8R,9S,10R,13S,14S)-4-hydroxy-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-3,17-dione; SMR000058722; DSSTox_CID_14113; DSSTox_RID_79116; DSSTox_GSID_34113; CAS-566-48-3; 4-Androsten-4-ol-3,17-dione; formestano; formestanum; SaveCream; Lentaron Depot; 4-hydroxyandrostene-3,17-dione; Formestane, solid; NCGC00015070-04; NCGC00164380-02; Lentaron (TN); Formestane (INN); CGP 32 349; Lentaron(R)17-dione; Opera_ID_865; SCHEMBL25717; MLS001148070; Androst-4-ene-3, 4-hydroxy-; DTXSID3034113; 4-hydroxy-Delta4-androstenedione; CTK7H2849; OSVMTWJCGUFAOD-KZQROQTASA-N; BDBM225704; CS333; HMS2090I22; HMS2234J06; HMS3715G16; BCP03066; HY-B0697; ZINC3919580; Tox21_112111; Tox21_113509; Tox21_302286; 4-hydroxy-4-androstene-3.17-dione; MFCD00057814; NSC282175; s2208; AKOS015895451; Tox21_112111_1; CCG-221077; CS-2938; DB08905; NSC-282175; NCGC00164380-01; NCGC00255321-01; NCGC00344560-01; AK115686; CC-28824; LS-19455; NCI60_002316; SC-12219; AB2000542; TR-019862; ST24043795; D07260; AB00572625-07; 566F483; A831133; C-18875; SR-01000721948; Lentaron(R); 17-dione; CGP-32349; NSC 282175; Q3077501; SR-01000721948-2; (8R,9S,10R,13S,14S)-10,13-dimethyl-4-oxidanyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-3,17-dione; (8R,9S,10R,13S,14S)-4-hydroxy-10,13-dimethyl-1,6,7,8,9,10,11,12,13,14,15,16-dodecahydro-3H-cyclopenta[a]phenanthrene-3,17(2H)-dione; (8R,9S,10R,13S,14S)-4-hydroxy-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-3,17-quinone; Formestane; B, Aromatase inhibitor
Formic acid C1 acid
Forskolin (3R,4aR,5S,6S,6aS,10S,10aR,10bS)-5-(Acetyloxy)-3-ethenyldodecahydro-6,10,10b-trihydroxy-3,4a,7,7,10a-pentamethyl-1H-naphtho[2,1-b]pyran-1-one; Colforsin [USAN:INN]; 7-beta-Acetoxy-8,13-epoxy-1-alpha,6-beta,9-alpha-trihydroxylabd-14-en-11-one
Foscarnet Dihydroxyphosphinecarboxylic acid oxide; Foscarnet; Foscarnet
Framycetin sulphate Neomycin sulfate; Neomycin sulfate [USP]; Biosol (Veterinary)
Fructose D-Fructose; D-Arabino-Hex-2-ulo-Pyranose; D-Fru; D-Fructopyranose; D-Fructopyranoside; D-Fructose; Fru; Fructopyranose; Fructopyranoside; Fructose; CHEBI:37714; 6347-01-9; [14C]-Fructose; D-arabino-Hex-2-ulopyranose; SCHEMBL239448; CHEMBL2325229; CTK2F9011; LKDRXBCSQODPBY-VRPWFDPXSA-N; AKOS004910390; F0317; C05003; Q27117234; EB37038E-44A6-4AF7-B0D8-47A315AD2F74; (3S,4R,5R)-2-(hydroxymethyl)tetrahydro-2H-pyran-2,3,4,5-tetraol; Fructose; AI3-23514
Fulvestrant (7alpha,17beta)-7-[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5(10)-triene-3,17-diol; Fulvestrant; Fulvestrant
Fumagillin (2E,4E,6E,8E)-2,4,6,8-Decatetraenedioic acid, 1-[(3R,4S,5S,6R)-5-Methoxy-4-[(2R,3R)-2-methyl-3-(3-methyl-2-buten-1-yl)-2-oxiranyl]-1-oxaspiro[2.5]oct-6-yl]ester; Fumagillin; H-3
Furaltadone 5-(4-Morpholinylmethyl)-3-(((5-nitro-2-furanyl)methylene)amino)-2-oxazolidinone; Furaltadon; F-150
Furazolidone 3-[[(5-Nitro-2-furanyl)methylene]amino]-2-oxazolidinone; furazolidone; Nitrofurazolidone; Furoxone; Furazolidine; Nitrofuroxon; Furazolidon; Diafuron; Furaxone; Furazol; Furazon; Furidon; 67-45-8; Nitrofurazolidonum; Furozolidine; Nifurazolidone; Coryzium; Furoxane; Nifulidone; Roptazol; Tikofuran; Topazone; Trichofuron; Tricofuron; Tricoron; Trifurox; Furall; Furaxon; Furoxal; Furoxon; Giardil; Giarlam; Medaron; Neftin; Nicolen; Optazol; Ortazol; Puradin; Corizium; Enterotoxon; Sclaventerol; Viofuragyn; Bifuron; Furovag; Nifuran; Furox; Furoxone Swine Mix; Usaf ea-1; 3-(5'-Nitrofurfuralamino)-2-oxazolidone; N-(5-Nitro-2-furfurylidene)-3-amino-2-oxazolidone; Furazolidona; Furazolidonum; NF 180 custom mix ten; 3-(5-Nitrofurfurylideneamino)-2-oxazolidinone; 5-Nitro-N-(2-oxo-3-oxazolidinyl)-2-furanmethanimine; N-(5-Nitro-2-furfurylidene)-3-aminooxazolidine-2-one; 3-[(5-Nitrofurfurylidene)amino]-2-oxazolidinone; Nifurazolidonum; Furazolum; 3-((5-Nitrofurylidene)amino)-2-oxazolidone; 3-((5-Nitrofurfurylidene)amino)-2-oxazolidone; 3-((5-Nitrofurfurylidene)amino)-2-oxazolidinone; 3-[(5-Nitrofurylidene)amino]-2-oxazolidone; 3-(((5-Nitro-2-furanyl)methylene)amino)-2-oxazolidinone; 3-[(5-Nitrofurfurylidene)amino]-2-oxazolidone; 3-{[(5-nitrofuran-2-yl)methylidene]amino}-1,3-oxazolidin-2-one; 3-[(E)-(5-nitrofuran-2-yl)methylideneamino]-1,3-oxazolidin-2-one; 2-Furanmethanimine, 5-nitro-N-(2-oxo-3-oxazolidinyl)-; MLS000069727; 3-[[(5-Nitro-2-furanyl)methylene]amino]-2-oxazolidinone; 3-{[(5-Nitro-2-furanyl)methylene]amino}-2-oxazolidinone; Furazolidonum [INN-Latin]; NSC6469; F-8900; Furazolidona [INN-Spanish]; NF-180; NSC-6469; 2-Oxazolidinone, 3-((5-nitrofurfurylidine)amino)-; MFCD00010550; NF 180; NCGC00095304-02; Furox Aerosol Powder (Veterinary); SMR000058228; 2-Oxazolidinone, 3-[[(5-nitro-2-furanyl)methylene]amino]-; UNII-5J9CPU3RE0; DSSTox_CID_21997; DSSTox_RID_79899; DSSTox_GSID_41997; 2-Oxazolidinone, 3-((5-nitrofurfurylidene)amino)-; CCRIS 1540; Fiurox aerosol powder; HSDB 7036; NSC 6469; EINECS 200-653-3; Furazolidone [INN:BAN]; 2-Oxazolidinone, 3-(((5-nitro-2-furanyl)methylene)amino)-; Furoxone (TN); FZL; AI3-50103; 3-((5-Nitrofurfurylidine)amino)-2-Oxazolidinone; 3-[(5-Nitrofurfurylidine)amino]-2-Oxazolidinone; 5J9CPU3RE0; SR-05000001632; 2-Oxazolidinone, 3-[(5-nitrofurfurylidene)amino]-; 2-Oxazolidinone, 3-[(5-nitrofurfurylidine)amino]-; Furazolidone (USP/INN); CHEBI:5195; 3-[(1E)-2-(5-nitro(2-furyl))-1-azavinyl]-1,3-oxazolidin-2-one; CAS-67-45-8; component of Topazone; component of Tricofuron; Opera_ID_256; Prestwick2_000808; Prestwick3_000808; Spectrum5_000742; CHEMBL1103; SCHEMBL64996; BSPBio_000675; BSPBio_002052; MLS001304180; BIDD:GT0182; SPECTRUM1500309; BPBio1_000743; HMS500E07; 3-[(E)-(5-nitro-2-furyl)methyleneamino]oxazolidin-2-one; 3-[[(5-Nitro-2-furanyl)methylene]-amino]-2-oxazolidinone; PLHJDBGFXBMTGZ-WEVVVXLNSA-N; 3-{[(5-nitro-2-furyl)methylene]amino}-1,3-oxazolidin-2-one; HMS1920O22; HMS2091H03; Pharmakon1600-01500309; HY-B1336; ZINC7997571; Tox21_111502; 3-{[(E)-(5-nitrofuran-2-yl)methylidene]amino}-1,3-oxazolidin-2-one; CCG-40233; GA1580; NSC757038; s4528; SBB057396; STK388219; AKOS001678302; Furazolidone, Vetec(TM) reagent grade; Tox21_111502_1; CS-4897; DB00614; NE48875; NSC-757038; Furazolidone 100 microg/mL in Methanol; IDI1_000085; WLN: T5OJ BNW E1UN- AT5NVOTJ; NCGC00095304-01; NCGC00095304-03; NCGC00095304-04; NCGC00095304-05; NCGC00188974-01; AC-11695; H863; SC-12651; ST024756; SBI-0051388.P003; AB1009283; LS-100676; TR-022655; AB00443658; 3-(5-nitrofurfurylideneamino)oxazolidin-2-one; A16011; C07999; D00830; AB00052000_03; Furazolidone, VETRANAL(TM), analytical standard; A835757; Furazolidone, Antibiotic for Culture Media Use Only; SR-05000001632-1; SR-05000001632-3; BRD-K10647544-001-02-0; BRD-K11756522-001-03-2; BRD-K11756522-001-04-0; 3-[(E)-(5-nitro-2-furanyl)methylideneamino]-2-oxazolidinone; 3-[[(5-Nitro-2-furanyl)methylene]amino]-2-oxazolidinone, 9CI; 3-([(5-Nitro-2-furyl)methylidene]amino)-1,3-oxazolidin-2-one #; 3-{[(1E)-(5-nitro-2-furyl)methylene]amino}-1,3-oxazolidin-2-one; Furazolidone, United States Pharmacopeia (USP) Reference Standard; InChI=1/C8H7N3O5/c12-8-10(3-4-15-8)9-5-6-1-2-7(16-6)11(13)14/h1-2,5H,3-4H2/b9-5; Furazolidone; AI3-50103
Furosemide 5-(Aminosulfonyl)-4-chloro-2-[(2-furanylmethyl)amino]benzoic acid; Furosemide; 5-18-09-00555 (Beilstein Handbook Reference)
Fusaric acid 5-Butyl-2-pyridinecarboxylic acid; Fusaric acid; 5-22-02-00384 (Beilstein Handbook Reference)
Fusidanes Fusidic Acid
Gabapentin 1-(Aminomethyl)cyclohexaneacetic acid; Gabapentin
Galactose D-Galactose; D-Gal; D-Galactopyranose; D-Galactopyranoside; D-Galactose; Gal; Galactopyranose; Galactopyranoside; Galactose; D-(+)-Galactose; 10257-28-0; cerebrose; Galactose, pure; CHEBI:4139; (+)-Galactose; AI3-18440; (3R,4S,5R,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol; D-Glucose-2-13C; SMR000857326; Echocon; Echovist; brain sugar; NSC-8102; dl-Galactose; NCGC00159442-02; EINECS 233-595-2; D-Galactose (9CI); DSSTox_CID_3088; Galactose, D- (8CI); Epitope ID:141794; Shu 450; Shu 454; Shu-454; D-(+)-Galactose Anhydrous; DSSTox_RID_76869; DSSTox_GSID_23088; SCHEMBL38935; MLS001335983; MLS001335984; CHEMBL195923; (3R,4S,5R,6R)-6-(Hydroxymethyl)tetrahydro-2H-pyran-2,3,4,5-tetraol; DTXSID0023088; CTK0I1082; D-Galactose microparticulate form; WQZGKKKJIJFFOK-SVZMEOIVSA-N; BDBM228805; HMS2230N07; 40825-89-6; S HU 450; S HU 454; Tox21_111672; s3849; AKOS030573864; CAS-59-23-4; D-Galactose plant origin (ex peach gum); NCGC00166082-01; AS-46931; LS-71021; AI3-09083; G0008; C00124; S-1121; O_FULL_1_GS_94; Q27106307; (3R,4S,5R,6R)-6-methyloltetrahydropyran-2,3,4,5-tetrol; 90881-70-2; Galactose; 4-01-00-04336 (Beilstein Handbook Reference)
Gallium nitrate Nitric acid, Gallium salt; Gallium nitrate; CCRIS 4493
Ganirelix N-Acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-tyrosyl-N6-[bis(ethylamino)methylene]-D-lysyl-L-leucyl-N6-[bis(ethylamino)methylene]-L-lysyl-L-prolyl-D-alaninamide; Ganirelix; Ganirelix
Gemfibrozil 5-(2,5-Dimethylphenoxy)-2,2-dimethylpentanoic acid; Gemfibrozil; BRN 1881200
Geneticin O-2-Amino-2,7-dideoxy-D-glycero-alpha-D-gluco-heptopyranosyl-(1->4)-O-[3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl-(1->6)]-2-deoxy-D-streptamine; Antibiotic G 418; G 418
Genistein genistein; 446-72-0; Prunetol; Genisteol; 4',5,7-Trihydroxyisoflavone; Genisterin; Sophoricol; 5,7,4'-Trihydroxyisoflavone; 5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one; Bonistein; Differenol A; Genestein; NPI 031L; 5,7-dihydroxy-3-(4-hydroxyphenyl)chromen-4-one; 5,7-Dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-3-(4-hydroxyphenyl)-; C.I. 75610; SIPI 807-1; UNII-DH2M523P0H; NSC 36586; CCRIS 7675; 5,7-Dihydroxy-3-(4-hydroxyphenyl)-4-benzopyrone; NSC36586; CHEMBL44; EINECS 207-174-9; MFCD00016952; BRN 0263823; ISOFLAVONE, 4',5,7-TRIHYDROXY-; MLS000738127; DH2M523P0H; CHEBI:28088; TZBJGXHYKVUXJN-UHFFFAOYSA-N; NSC-36586; GEN; NCGC00015479-09; DSSTox_CID_2308; DSSTox_RID_76542; Genistein, 99%, synthetic; DSSTox_GSID_22308; CAS-446-72-0; Lactoferrin-genistein; 4',5, 7-Trihydroxyisoflavone; SR-01000075498; PTI G4660 (Genistein); STO514; HSDB 7475; PTI G4660; PTI-G4660; SIPI-9764-I; 3kgt; 3kgu; Genistein, 8; Genistein,(S); PTI-G 4660; 4′ ,5,7-Trihydroxyisoflavone; TNP00151; Genistein [USAN]; GENISTEIN (ENDOCRINE DISRUPTER); Genistein (flavonoid); PubChem9852; Spectrum_000320; Tocris-1110; 1x7r; 2qa8; Genistein 85% HPLC; SpecPlus_000305; Spectrum2_000638; Spectrum3_000678; Spectrum4_001543; Spectrum5_000106; Lopac-G-6649; 4',7-Trihydroxyisoflavone; MolMap_000022; UPCMLD-DP096; G 6649; Bio 300; 4,5,7-Trihydroxyisoflavone; Isoflavone,5,7-trihydroxy-; Lopac0_000520; Oprea1_224620; Oprea1_437815; SCHEMBL19166; BSPBio_002375; KBioGR_002006; KBioGR_002564; KBioSS_000800; KBioSS_002573; SPECTRUM210296; 5-18-04-00594 (Beilstein Handbook Reference); BIDD:ER0113; DivK1c_006401; Genistein, analytical standard; SPBio_000636; 4',5,7-trihydroxy-Isoflavone; GTPL2826; MEGxp0_000568; NPI-031L; 4,5,7-Trihydroxy Iso-Flavone; DTXSID5022308; UPCMLD-DP096:001; ACon1_001065; BDBM19459; cid_5280961; KBio1_001345; KBio2_000800; KBio2_002564; KBio2_003368; KBio2_005132; KBio2_005936; KBio2_007700; KBio3_001595; KBio3_003042; AOB5073; CHEBI: 28088; cMAP_000086; Bio1_000445; Bio1_000934; Bio1_001423; HMS2271K09; HMS3261H21; HMS3267K14; HMS3412I13; HMS3428M01; HMS3649B22; HMS3654D17; HMS3676I13; HMS3742I07; SIPI-807-1; ACT05962; ALBB-015886; BCP07581; KS-00000MH8; Tox21_110161; Tox21_201428; Tox21_300585; Tox21_500520; AC-472; BBL010484; CCG-38551; CG-009; FW-635I-2; LMPK12050218; s1342; SBB066115; STK801619; WHO 11073; ZINC18825330; AKOS001590147; ENDOCRINE DISRUPTOR (GENISTEIN) (SEE ALSO GENISTEIN (446-72-0)); Tox21_110161_1; CS-1534; DB01645; KS-5128; LP00520; LS-1266; MCULE-4857649752; SB17235; SDCCGSBI-0050503.P003; SMP1_000133; Genistein; 4',5,7-Trihydroxyisoflavone; NCGC00015479-01; NCGC00015479-02; NCGC00015479-04; NCGC00015479-05; NCGC00015479-06; NCGC00015479-07; NCGC00015479-08; NCGC00015479-10; NCGC00015479-11; NCGC00015479-12; NCGC00015479-13; NCGC00015479-14; NCGC00015479-15; NCGC00015479-16; NCGC00015479-17; NCGC00015479-18; NCGC00015479-19; NCGC00015479-20; NCGC00025005-01; NCGC00025005-02; NCGC00025005-03; NCGC00025005-04; NCGC00025005-05; NCGC00025005-06; NCGC00025005-07; NCGC00169711-01; NCGC00169711-02; NCGC00254275-01; NCGC00258979-01; NCGC00261205-01; 690224-00-1; AK161745; HY-14596; NCI60_003369; SC-04581; SMR000112580; ST056352; SY050124; AB1004490; EU-0100520; FT-0603395; G0272; N1861; SW203763-2; 46G720; C06563; G-2535; Genistein, synthetic, >=98% (HPLC), powder; J10015; K00046; S-7751; US8552057, 2; AB00052696_09; AB00052696_12; A826657; Q415957; Genistein, primary pharmaceutical reference standard; Q-100484; SR-01000075498-1; SR-01000075498-3; SR-01000075498-6; 3-(4-hydroxyphenyl)-5,7-bis(oxidanyl)chromen-4-one; BRD-K43797669-001-02-3; BRD-K43797669-001-03-1; BRD-K43797669-001-10-6; Genistein, from Glycine max (soybean), ~98% (HPLC); SR-01000075498-10; 5,7-dihydroxy-3-(4-hydroxyphenyl)-1-benzopyran-4-one; F0001-2388; 4H-1-Benzopyran-4-one,7-dihydroxy-3-(4-hydroxyphenyl)-; UNII-71B37NR06D component TZBJGXHYKVUXJN-UHFFFAOYSA-N; Genistein, United States Pharmacopeia (USP) Reference Standard; Genistein, Pharmaceutical Secondary Standard; Certified Reference Material; 4 inverted exclamation marka,5,7-Trihydroxyisoflavone; 5,7-Dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 5,7-DIHYDROXY-3-(4-HYDROXYPHENYL)-4H-1-BENZOPYRAN-4-ONE; 4',5,7-TRIHYDROXYISOFLAVONE; PRUNETOL; GENISTEOL; C.I. 75610
Gentamicin gentamicin; Gentavet; Gentamicins; Gentamycinum; Cidomycin; Garasol; Refobacin; Uromycine; Refobacin TM; Gentocin; Gentamicin sulphate sterile; Gentacycol; Gentamicine [INN-French]; Gentamicinum [INN-Latin]; Gentamycin-creme [German]; Gentamicina [INN-Spanish]; 1403-66-3; HSDB 3087; EINECS 215-765-8; Gentamicinum; GentamiciGentamicine; CEAZRRDELHUEMR-UHFFFAOYSA-N; Gentamycin-creme; Gentamycins; Oksitselanim; Centicin; Lyramycin; Septigen; Gentamicin (TN); Gentamicin (BAN); Gentamicin [INN]; Gentamicin [INN:BAN]; 4,6-diamino-3-{[3-deoxy-4-c-methyl-3-(methylamino)pentopyranosyl]oxy}-2-hydroxycyclohexyl 2-amino-2,3,4,6,7-pentadeoxy-6-(methylamino)heptopyranoside; SCHEMBL537630; CHEMBL329592; GTPL2427; SCHEMBL19996168; STL454325; AKOS015961211; DB00798; J4.074F; 2-[4,6-diamino-3-[3-amino-6-(1-methylaminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-methylaminooxane-3,5-diol; AC-13386; LS-71146; FT-0626646; D08013; 123871-EP2292088A1; 123871-EP2295422A2; 123871-EP2295439A1; Q422482; Gentamicin C1; gentamicin; UNII-I904Y9FPPV; 25876-10-2; I904Y9FPPV; (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-[(1R)-1-(methylamino)ethyl]tetrahydropyran-2-yl]oxy-2-hydroxy-cyclohexoxy]-5-methyl-4-(methylamino)tetrahydropyran-3,5-diol; D-Streptamine, O-2-amino-2,3,4,6,7-pentadeoxy-6-(methylamino)-alpha-D-ribo-heptopyranosyl-(1-4)-O-(3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl-(1-6))-2-deoxy-; AC1L2HZV; 51G; CHEMBL463809; DTXSID9023091; SCHEMBL19270300; Gentamicin C1 sulfate (G031); CEAZRRDELHUEMR-CAMVTXANSA-N; HMS2090K12; RKL10091; ZINC8143541; BDBM50366389; D-Streptamine, O-2-amino-2,3,4,6,7-pentadeoxy-6-(methylamino)-.alpha.-D-ribo-heptopyranosyl-(1.fwdarw.4)-O-[3-deoxy-4-C-methyl-3-(methylamino)-.beta.-L-arabinopyranosyl-(1.fwdarw.6)]-2-deoxy-; LS-71147; C07656; AB01275504-01; Q27280589; UNII-T6Z9V48IKG component CEAZRRDELHUEMR-CAMVTXANSA-N; (1R,2S,3S,4R,6S)-4,6-Diamino-3-{[3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl]oxy}-2-hydroxycyclohexyl 2-amino-2,3,4,6,7-pentadeoxy-6-(methylamino)-alpha-D-ribo-heptopyranoside; (1S,2S,3R,4S,6R)-4,6-diamino-3-({(2R,3R,6S)-3-amino-6-[(1R)-1-(methylamino)ethyl]tetrahydro-2H-pyran-2-yl}oxy)-2-hydroxycyclohexyl 3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranoside; Gentamycin C1; gentamicin; CHEBI:27412; 1403-66-3; (1R,2S,3S,4R,6S)-4,6-diamino-3-[3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyloxy]-2-hydroxycyclohexyl 2-amino-2,3,4,6,7-pentadeoxy-6-(methylamino)-beta-L-lyxo-heptopyranoside; O-2-amino-2,3,4,6,7-pentadeoxy-6-(methylamino)-alpha-D-ribo-heptopyranosyl-(1-4)-O-(3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl-(1-6))-2-deoxy-D-streptamine; 25876-10-2; Sulmycin; SCHEMBL196202; CHEMBL195892; 403G663; Q27103118; (1R,2S,3S,4R,6S)-4,6-diamino-3-{[3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl]oxy}-2-hydroxycyclohexyl (6x)-2-amino-2,3,4,6,7-pentadeoxy-6-(methylamino)-alpha-D-erythro-heptopyranoside; Gentamicin [INN]; Cidomycin
Gentian violet N-[4-[Bis[4-(dimethylamino)phenyl]methylene]-2,5-cyclohexadien-1-ylidene]-N-methylmethanaminiumchloride (1:1); Basic Violet 3; C.I. 42555
Gibberellin A4 (1alpha,2beta,4aalpha,4bbeta,10beta)-2,4a-Dihydroxy-1-methyl-8-methylenegibbane-1,10-decarboxylic acid 1,4a-lactone; Gibberellin A4; EINECS 207-406-9
Ginsenoside RG1 Panaxoside A; Ginsenoside RG1; (3beta,6alpha,12beta)-3,12-Dihydroxydammar-24-ene-6,20-diyl bis-beta-D-Glucopyranoside
Gluconolactone D-Guconic acid, delta-Lactone; D-Gluconic acid, delta-lactone; AI3-19578
Glutamine L-Glutamine; L-glutamine; glutamine; 56-85-9; Levoglutamide; L-(+)-Glutamine; H-Gln-OH; Glutamic acid amide; Stimulina; Cebrogen; glumin; Levoglutamid; Glavamin; glutamic acid 5-amide; L-Glutamide; 2-aminoglutaramic acid; (S)-2,5-Diamino-5-oxopentanoic acid; Miglu-P; Polyglutamine; Saforis; L-2-Aminoglutaramidic acid; L-Glutamic acid gamma-amide; L-Glutamin; Glumin (amino acid); Glutamine (VAN); L-2-Aminoglutaramic acid; L-Glutamic acid 5-amide; (2S)-2-amino-4-carbamoylbutanoic acid; Levoglutamida; Levoglutamidum; 2-Aminoglutaramic acid, L-; (2S)-2,5-diamino-5-oxopentanoic acid; FEMA No. 3684; Levoglutamidum [INN-Latin]; Levoglutamida [INN-Spanish]; Levoglutamina; Pentanoic acid, 2,5-diamino-5-oxo-, (S)-; GLUTAMINE, L-; L-Glutamid; 2,5-Diamino-5-oxopentanoic acid, (S)-; AI3-24392; Glutamine [USP]; NSC 27421; Nutrestore; UNII-0RH81L854J; BRN 1723797; L-Glutaminsaeure-5-amid; EINECS 200-292-1; MFCD00008044; CHEMBL930; CHEBI:18050; ZDXPYRJPNDTMRX-VKHMYHEASA-N; d(-)-glutamine; 0RH81L854J; Glutamine (USP); gln; L-gln; Glutamine (L-Glutamine); Poly(glutamine); Levoglutamide [DCF:INN]; L(+)-Glutamine, 99%; gamma-Glutamine; .gamma.-Glutamine; Glutamine [USAN]; GLUTAMINE (D); (2S)-2,5-diamino-5-oxopentanoate; L-Glutamic acid .gamma.-amide; (2S)-5-amino-2-azaniumyl-5-oxopentanoate; Glutamine [USAN:USP:INN]; L(+)-Glutamine, specified according to the requirements of USP; laevo-glutamine; CCRIS 9428; NSC-27421; 3h-l-glutamine; HSDB 8165; 1wdn; (S)-glutamine; [3H]glutamine; Nutrestore (TN); S(+)Glutamine; [14C]glutamine; [3H]-glutamine; L-Glutamine Powder; Cebrogen, Stimulina; L-Glutamine,(S); [14C]-glutamine; H-Gln; L-Alanyl-L-glutamide; L-Glutamine [JAN]; Spectrum_000131; L-Glutamine [JAN]; SpecPlus_000380; L-Glutamine (JP17); GLUTAMINE (L); L-Glutamine, homopolymer; Spectrum2_001377; Spectrum3_001416; Spectrum4_001709; Spectrum5_000418; L-Glutamine, 98.5%; bmse000038; bmse001014; SCHEMBL7453; Lopac0_000549; BSPBio_003092; GTPL723; KBioGR_002038; KBioSS_000591; 26700-71-0; 4-04-00-03038 (Beilstein Handbook Reference); KSC269S9J; DivK1c_006476; SPECTRUM1500987; N-(2)-L-alanyl-L-glutamine; S(+)-Glutamic acid 5-amide; SPBio_001334; L-[3,4-3H(N)]glutamine; GTPL4633; GTPL4634; DTXSID1023100; SCHEMBL19240116; BDBM18121; CTK1G9994; KBio1_001420; KBio2_000591; KBio2_003159; KBio2_005727; KBio3_002312; HMS3261N19; HMS3264C03; Pharmakon1600-01300018; Pharmakon1600-01500987; (S)-2,5-Diamino-5-oxopentanoate; HY-N0390; KS-00000AA5; KS-000010SX; ZINC1532526; (2S)-2-amino-4-carbamoylbutanoate; Tox21_500549; ANW-32592; CCG-38853; EBD968977; NSC759628; NSC760081; s1749; AKOS015854078; (S)-2-Amino-4-carbamoyl-butyric acid; AM81759; CS-1947; DB00130; LP00549; MCULE-8718820108; NE10548; NSC-759628; NSC-760081; RTC-066534; SDCCGMLS-0066691.P001; SDCCGSBI-0050532.P005; NCGC00093936-01; NCGC00093936-02; NCGC00093936-03; NCGC00093936-04; NCGC00093936-05; NCGC00261234-01; (2S)-2,5-diamino-5-oxo-pentanoic acid; AS-11765; BP-13284; LS-71898; SBI-0050532.P003; AB0004431; AB1002635; L-Glutamine, BioUltra, >=99.5% (NT); ST2407066; TC-066534; EU-0100549; FT-0627836; G0063; L-Glutamine, SAJ special grade, >=99.0%; C00064; D00015; G 3126; M02960; 16575-EP2269996A1; 16575-EP2270004A1; 16575-EP2275412A1; 16575-EP2277861A1; 16575-EP2277876A1; 16575-EP2281563A1; 16575-EP2281815A1; 16575-EP2281824A1; 16575-EP2284157A1; 16575-EP2284171A1; 16575-EP2286812A1; 16575-EP2289876A1; 16575-EP2289883A1; 16575-EP2289892A1; 16575-EP2289893A1; 16575-EP2292611A1; 16575-EP2292614A1; 16575-EP2295055A2; 16575-EP2295401A2; 16575-EP2295411A1; 16575-EP2295416A2; 16575-EP2295417A1; 16575-EP2295429A1; 16575-EP2298312A1; 16575-EP2298748A2; 16575-EP2298780A1; 16575-EP2301533A1; 16575-EP2301940A1; 16575-EP2302382A2; 16575-EP2302383A2; 16575-EP2305640A2; 16575-EP2305652A2; 16575-EP2305663A1; 16575-EP2305688A1; 16575-EP2305689A1; 16575-EP2305695A2; 16575-EP2305696A2; 16575-EP2305697A2; 16575-EP2305698A2; 16575-EP2308844A2; 16575-EP2308845A2; 16575-EP2308846A2; 16575-EP2311453A1; 16575-EP2311806A2; 16575-EP2316459A1; 29474-EP2272827A1; 29474-EP2277867A2; 29474-EP2280003A2; 29474-EP2292088A1; 29474-EP2292611A1; 29474-EP2295410A1; 29474-EP2301939A1; 29474-EP2311842A2; AB00173347-03; AB00173347_04; L-Glutamine, ReagentPlus(R), >=99% (HPLC); L-Glutamine, Vetec(TM) reagent grade, >=99%; 008G044; 141066-EP2269996A1; 141066-EP2292625A1; Q181619; 7FBA778C-D6B8-495C-BFE7-1CB8EC4ABEAB; J-521645; Q-100459; BRD-K83896451-001-01-8; F0001-1471; L-Glutamine, certified reference material, TraceCERT(R); Z1250208676; UNII-0O72R8RF8A component ZDXPYRJPNDTMRX-VKHMYHEASA-N; (S)-2,5-Diamino-5-oxopentanoic acid; L-Glutamic acid 5-amide; Glutamine, United States Pharmacopeia (USP) Reference Standard; UNII-5L555N1902 component ZDXPYRJPNDTMRX-VKHMYHEASA-N; L-Glutamine, gamma-irradiated, BioXtra, suitable for cell culture; L-Glutamine, Pharmaceutical Secondary Standard; Certified Reference Material; L-Glutamine Solution 200 mM, 29.23 mg/mL in saline, solution, suitable for cell culture; L-Glutamine solution, 200 mM, Hybri-Max(TM), sterile-filtered, suitable for hybridoma; L-Glutamine solution, 200 mM, solution, sterile-filtered, BioXtra, suitable for cell culture; L-Glutamine, meets USP testing specifications, cell culture tested, 99.0-101.0%, from non-animal source; L-Glutamine, PharmaGrade, Ajinomoto, USP, Manufactured under appropriate GMP controls for pharma or biopharmaceutical production, suitable for cell culture; Glutamine [USAN:USP:INN]; 4-04-00-03038 (Beilstein Handbook Reference)
Glutaric acid Pentanedioic acid; Glutaric acid; 4-02-00-01934 (Beilstein Handbook Reference)
Glutathione L-gamma-Glutamyl-L-cysteinylglycine; glutathione; 70-18-8; Glutathion; L-Glutathione; Isethion; Tathion; reduced glutathione; Glutathione-SH; Glutinal; L-Glutathione reduced; Deltathione; Neuthion; Copren; Glutide; Tathione; Triptide; Ledac; GSH; Glutatione; Glutatiol; Panaron; gamma-L-Glutamyl-L-cysteinylglycine; Glutathione SH; L-Glutatione; Agifutol S; Glutathione (reduced); L-gamma-glutamyl-L-cysteinylglycine; gamma-L-glutamyl-L-cysteinyl-glycine; glutathione reduced; 5-L-Glutamyl-L-cysteinylglycine; Glutathione [JAN]; gamma-L-Glutamylcysteinylglycine; glutathione red; red. glutathione; Bakezyme RX; UNII-GAN16C9B8O; (S)-2-Amino-5-(((R)-1-((carboxymethyl)amino)-3-mercapto-1-oxopropan-2-yl)amino)-5-oxopentanoic acid; L-Glutathione reduce; Glycine, L-gamma-glutamyl-L-cysteinyl-; CCRIS 2094; N-(N-gamma-L-Glutamyl-L-cysteinyl)glycine; N-(N-L-gamma-Glutamyl-L-cysteinyl)glycine; L-Glutathione, reduced; glycine, N-(N-L-gamma-glutamyl-L-cysteinyl)-; EINECS 200-725-4; NSC 400639; GAN16C9B8O; L-glutamyl-L-cysteinylglycine; CHEBI:16856; RWSXRVCMGQZWBV-WDSKDSINSA-N; (2S)-2-amino-5-[[(2R)-1-(carboxymethylamino)-1-oxo-3-sulfanylpropan-2-yl]amino]-5-oxopentanoic acid; DSSTox_CID_3101; (2S)-2-amino-4-{[(1R)-1-[(carboxymethyl)carbamoyl]-2-sulfanylethyl]carbamoyl}butanoic acid; DSSTox_RID_76875; DSSTox_GSID_23101; gamma-Glutamylcysteinylglycine; [Glu(-Cys)]n-Gly; phytochelatins; MFCD00065939; Phytochelatin; CAS-70-18-8; (S)-2-Amino-5-((R)-1-(carboxymethylamino)-3-mercapto-1-oxopropan-2-ylamino)-5-oxopentanoic acid; Glutathione, 98%, for analysis, reduced; Glycine, L-.gamma.-glutamyl-L-cysteinyl-; SR-05000002567; Glutathione [BAN:JAN]; L-Glutathione reduced form; ReadiSorb; Glutathione; NSC400639; 1lbk; NCGC00094976-01; AK-48453; Tathion (TN); Glutathione (JP17); PubChem20020; Spectrum_000419; 1oe7; 1oe8; 1r4w; C(N-.gamma.Glu-)G; Reduced Glutathione,(S); Spectrum2_001500; Spectrum3_000946; Spectrum4_001056; Spectrum5_000940; Glutathione, Reduced Form; bmse000185; bmse000952; bmse000956; Glutathione (Reduced type); Cys(N-.gamma.Glu-)-Gly; SCHEMBL9167; CHEMBL1543; KBioGR_001352; KBioSS_000899; KSC377E2T; MLS001333069; DivK1c_000075; SPECTRUM1502248; SPBio_001519; gamma-glutamyl-cysteinyl-glycine; GTPL6737; DTXSID6023101; L-?-glutamyl-L-cysteinylglycine; L-Glutathione reduced, 97.0%; CHEBI:60836; CTK2H7229; HMS500D17; KBio1_000075; KBio2_000899; KBio2_003467; KBio2_006035; KBio3_002012; KS-00000GCC; (gamma-Glutamylcysteine)n-glycine; L-g-glutamyl-L-cysteinyl-glycine; L-?-glutamyl-L-cysteinyl-glycine; NINDS_000075; HMS1921N22; Pharmakon1600-01502248; Poly(gamma-glutamylcysteine)glycine; HY-D0187; L-Glutathione reduced, >=98.0%; ZINC3830891; gam.-L-Glutamyl-L-cysteinyl-glycine; Tox21_111371; ANW-43980; BDBM50422268; CCG-38876; L-gamma-glutamyl-L-cysteinyl-glycine; NSC758199; s4606; AKOS015999135; Tox21_111371_1; CS-7948; DB00143; MCULE-3371744018; NSC-758199; SDCCGMLS-0066687.P001; .gamma.-L-Glutamyl-L-cysteinyl-glycine; IDI1_000075; N-(N-L-?-Glutamyl-L-cysteinyl)glycine; Pharm Biol 11: 539 (1968); SMP1_000247; NCGC00264046-02; DS-14675; LS-72665; SC-18300; SMR000857220; ST097777; SBI-0051743.P002; AB2000729; AX8132398; L-Glutathione reduced, BioXtra, >=98.0%; B7775; FT-0627837; G0074; ST24026560; 98726-08-0; Glycine, N-(N-L-gamma-glutamyl-L-cysteinyl); N-(N-L-.gamma.-Glutamyl-L-cysteinyl)glycine; A16158; C00051; C02471; D00014; G-3980; Y-8983; AB00443568_03; C-33528; Q116907; SR-05000002567-1; SR-05000002567-2; L-Glutathione reduced, Vetec(TM) reagent grade, >=98%; Z2183947556; Glutathione, European Pharmacopoeia (EP) Reference Standard; Glutathione, United States Pharmacopeia (USP) Reference Standard; Glutathione, Pharmaceutical Secondary Standard; Certified Reference Material; L-Glutathione reduced, cell culture tested, BioReagent, >=98.0%, powder; N5-((R)-1-((carboxymethyl)amino)-3-mercapto-1-oxopropan-2-yl)-L-glutamine; 4-(N-{(1R)-1-[N-(carboxymethyl)carbamoyl]-2-sulfanylethyl}carbamoyl)(2S)-2-ami nobutanoic acid; N-(N-L-gamma-Glutamyl-L-cysteinyl)glycine; CCRIS 2094
Glycine glycine; 2-Aminoacetic acid; 56-40-6; aminoacetic acid; Glycocoll; Aminoethanoic acid; Glycolixir; Glycosthene; Aciport; Glicoamin; H-Gly-OH; Padil; L-Glycine; Hampshire glycine; Amitone; Leimzucker; Acetic acid, amino-; Aminoazijnzuur; Glycine, non-medical; Sucre de gelatine; Gyn-hydralin; GLY (IUPAC abbrev); Glycinum; Corilin; Glycinum [INN-Latin]; Glicina [INN-Spanish]; Glycine [INN]; Glyzin; FEMA No. 3287; gly; Acide aminoacetique [INN-French]; Acido aminoacetico [INN-Spanish]; Acidum aminoaceticum [INN-Latin]; CCRIS 5915; HSDB 495; glycyl radical; AI3-04085; amino-Acetic acid; UNII-TE7660XO1C; NSC 25936; [14C]glycine; GLYCINE 1.5% IN PLASTIC CONTAINER; EINECS 200-272-2; MFCD00008131; CHEMBL773; AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER; Glycine iron sulphate (1:1); TE7660XO1C; CHEBI:15428; 2-aminoaceticacid; DHMQDGOQFOQNFH-UHFFFAOYSA-N; aminoacetate; NSC25936; Athenon; NSC-25936; polyglycine; NCGC00024503-01; Glicina; DSSTox_CID_667; Glycine, free base; Polyglycine II; Acido aminoacetico; Acide aminoacetique; DSSTox_RID_75720; DSSTox_GSID_20667; 25718-94-9; Acidum aminoaceticum; Glycine, 99%, ACS reagent; Glycine, 99+%, for analysis; Glykokoll; Aminoessigsaeure; Hgly; CAS-56-40-6; Glycine, labeled with carbon-14; Glycine [USP:INN]; 13682-92-3; H2N-CH2-COOH; Glycine, homopolymer (VAN); Aminoethanoate; amino-Acetate; 2-aminoacetate; Glycine; glycine USP; Glycine Technical; glycine-13c; [3H]glycine; Glycine, EP/USP; H-Gly; L-Gly; Gly-CO; Gly-OH; L-Glycine,(S); [14C]-glycine; Corilin (Salt/Mix); Glycine 1 M solution; PubChem18924; Tocris-0219; Glycine (H-Gly-OH); NH2CH2COOH; Glycine, >=99%; 13479-54-4; Aminoacetic acid,medicinal; Glycine (JP17/USP); Glycine, 99%, FCC; Biomol-NT_000195; bmse000089; bmse000977; WLN: Z1VQ; EC 200-272-2; Gly-253; GTPL727; AB-131/40217813; KSC205S9D; BPBio1_001222; GTPL4084; GTPL4635; DTXSID9020667; BDBM18133; Buffer Concentrate, pH 11.01; CTK1A5991; Glycine, >=99.0% (NT); Glycine, 98.5-101.5%; Pharmakon1600-01300021; BCP25965; CS-B1641; HY-Y0966; KS-000002MW; ZINC4658552; Glycine, ACS reagent, >=98.5%; Tox21_113575; ANW-32505; Glycine, 99%, natural, FCC, FG; LS-218; NSC760120; s4821; STL194276; Glycine, purum, >=98.5% (NT); Glycine, tested according to Ph.Eur.; AKOS000119626; Glycine, for electrophoresis, >=99%; Tox21_113575_1; AM81781; DB00145; MCULE-2415764032; NSC-760120; RTC-066530; Glycine, BioUltra, >=99.0% (NT); Glycine, BioXtra, >=99% (titration); Glycine, SAJ special grade, >=99.0%; NCGC00024503-02; NCGC00024503-03; 18875-39-3; AK-77854; BP-31024; BR-77854; Glycine, Vetec(TM) reagent grade, 98%; SC-26884; AB1002628; DB-029870; ST2416448; TC-066530; FT-0083159; FT-0600491; G0099; G0317; Glycine, ReagentPlus(R), >=99% (HPLC); A20662; Aminoacetic acid; Aminoethanoic acid; Glycocoll; C00037; D00011; M-6155; M03001; L001246; Q620730; SR-01000597729; Glycine, certified reference material, TraceCERT(R); Q-201300; SR-01000597729-1; Q27115084; B72BA06C-60E9-4A83-A24A-A2D7F465BB65; F2191-0197; Glycine, European Pharmacopoeia (EP) Reference Standard; Z955123660; Glycine, BioUltra, for molecular biology, >=99.0% (NT); InChI=1/C2H5NO2/c3-1-2(4)5/h1,3H2,(H,4,5; UNII-0O72R8RF8A component DHMQDGOQFOQNFH-UHFFFAOYSA-N; Glycine, United States Pharmacopeia (USP) Reference Standard; Glycine, Pharmaceutical Secondary Standard; Certified Reference Material; Tris-tricine buffer; Tris-glycine buffer; Tris glycine buffer concentrate; Glycine, analytical standard, for nitrogen determination according to Kjeldahl method; Glycine, from non-animal source, meets EP, JP, USP testing specifications, suitable for cell culture, >=98.5%; Glycine, meets analytical specification of Ph. Eur., BP, USP, 99-101% (based on anhydrous substance); Glycine, PharmaGrade, Ajinomoto, EP, JP, USP, manufactured under appropriate GMP controls for Pharma or Biopharmaceutical production, suitable for cell culture; Glycine, puriss. p.a., Reag. Ph. Eur., buffer substance, 99.7-101% (calc. to the dried substance); Aminoacetic acid; Acetic acid, amino-
Glycocyamine glycocyamine; guanidinoacetic acid; 352-97-6; 2-Guanidinoacetic acid; Guanidineacetic acid; Guanidoacetic acid; N-amidinoglycine; Betacyamine; Guanyl glycine; Betasyamine; Glykocyamin; guanidinoacetate; Guanidylacetic acid; GLYCINE, N-AMIDINO-; Guanidine, (carboxymethyl)-; glycine, N-(aminoiminomethyl)-; N-[AMINO(IMINO)METHYL]GLYCINE; N-carbamimidoylglycine; GUANIDINO ACETATE; N-(carbamimidoyl)glycine; Acetic acid, ((aminoiminomethyl)amino)-; N-(Aminoiminomethyl)glycine; NSC 1901; (carbamimidamido)acetic acid; 2-carbamimidamidoacetic acid; UNII-GO52O1A04E; EINECS 206-529-5; MFCD00004278; .alpha.-Guanidinoacetic acid; Glycine, N-amidino- (8CI); AI3-17119; CHEMBL281593; GO52O1A04E; CHEBI:16344; NSC1901; BPMFZUMJYQTVII-UHFFFAOYSA-N; Guanidoacetate; n-amidino-glycine; NMG; N-Guanylglycine; Acetic acid, [(aminoiminomethyl)amino]-; 2-[[Amino(imino)methyl]amino]acetic acid; 2-{[amino(imino)methyl]amino}acetic acid; 2-([AMINO(IMINO)METHYL]AMINO)ACETIC ACID; 2-(diaminomethylideneamino)acetic acid; amidinoglycine; Glucocyamine; Guanidylacetate; Guanidineacetate; a-Guanidinoacetate; b-Guanidinoacetate; GuanidineaceticAcid; beta-Guanidinoacetate; guanidine acetic acid; alpha-Guanidinoacetate; a-Guanidinoacetic acid; b-Guanidinoacetic acid; ACMC-209ifs; beta-Guanidinoacetic acid; GUANIDOACETIC_ACID; (carboxymethyl)-Guanidine; alpha-Guanidinoacetic acid; bmse000384; Guanidineacetic acid, 99%; 2-(amidinoamino)acetic acid; SCHEMBL33970; 2-carbamimidamido-acetic acid; Guanidine acetic acid, 99%; KSC492A2H; GTPL5325; (Diaminomethylenamino)-essigsaure; CTK3J2023; KS-00000AIO; [(aminoiminomethyl)amino]-Acetate; HMS3604I10; ZINC895314; NSC-1901; NSC26360; ANW-28166; BBL013464; BDBM50021601; HTS001798; NSC-26360; NSC227847; SBB028198; STL164350; [(aminoiminomethyl)amino]-Acetic acid; 2-[[Amino(imino)methyl]amino]acetate; AKOS005363765; DB02751; HY-W021448; MCULE-8327589872; NSC-227847; RTR-031933; ([Amino(imino)methyl]amino)acetic acid #; AK144672; AS-10760; SY015122; AB0008202; DB-069193; LS-174518; TR-031933; CS-0040590; FT-0626779; G0167; ST24040649; C00581; M-3558; Q2740979; W-106678; Acetic acid, ((aminoiminomethyl)amino)-